Global Meningococcal Disease Treatment Market, By Therapy Type (Antibiotics (Penicillin, Ampicillin, Chloramphenicol, and Ceftriaxone) and (Vaccines (Bivalent, Trivalent, and Tetravalent)), By Route of Administration (Injectable and Oral), By Distribution channel (Hospital Pharmacy, Retail Pharmacy, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 3,754.1 million in 2021 and is expected to exhibit a CAGR of 12.6% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Request Sample Report (Including Full TOC, Table & Figures) @
There are many vaccination options for meningococcal disease, which includes protein based and conjugate vaccines. The vaccines confer longer-lasting immunity and reduce the risk of transmission. In addition, meningococcal vaccines also protect people living outside the meningitis belt, making them an essential part of herd immunity. These vaccines have been in use since the 1970s, but only cover four of the serogroups. Although effective against the disease in adults, meningococcal polysaccharide vaccines don’t consistently generate immunity in young children, so it’s important to get vaccinated.
The growing approval of product launch for the treatment of meningococcal disease is expected to drive the market growth. For instance, in April 2020, The U.S. Food and Drug Administration (FDA) granted biologics license application for Sanofi’s MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in 2 years and older individuals.
In 2014, Pfizer Inc., a pharmaceutical company has launched Trumenba Vaccine for Meningitis B in the U.S. for 10 to 25 years old individuals, infected with meningitis caused by Neisseria meningitidis serogroup B.
Impact of Coronavirus (Covid-19) Pandemic
Due to the worldwide lockdown, all immunization program has been stopped and program schedule are changed in various countries as per the Covid-19 guidelines.
Research and development for activated vaccine and drug technology has been limited, as researchers need to stay at home during the lockdown.
Furthermore, in April 2020, University of Oxford U.K. has conducted a Covid-19 vaccine trial using Meningococcal vaccine placebo effect
Request PDF Brochure with Latest Insights @
Key Takeaways of the Global Meningococcal Disease Treatment Market:
The global meningococcal disease treatment market is expected to exhibit a CAGR of 12.6% over the forecast period, due to growing incidences of meningococcal disease, which is projected to drive the market growth during the forecast period. According to the World health Organization (WHO) article published in 2018, meningococcal meningitis is observed at worldwide level but the highest burden of this disease is in the meningitis belt of sub-Saharan Africa, around 30,000 cases are still reported each year from sub-Saharan Africa area.
Among therapy type, vaccine segment is accounted for the largest market share in 2020, owing to increasing R&D. For instance, in July 2020, Pfizer Inc., announced the initiation of phase 3 clinical trials of NCT04440163 of the pentavalent meningococcal vaccine candidate.
Key players operating in the global meningococcal disease treatment market include GlaxoSmithKline Plc., Novartis AG, Sanofi Pasteur Inc., Wockhardt Ltd., Kent Pharmaceuticals, Stravencon Limited., F. Hoffmann-La Roche Ltd., Athlone Laboratories, and Pfizer Inc.
Reasons to buy this Meningococcal Disease Treatment Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ Meningococcal Disease Treatment market size estimation and recent advancements in the industry are explained.
SPECIAL OFFER (Avail an Up-to 30% discount on this report ) @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Meningococcal Disease Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Meningococcal Disease Treatment Industry Impact
Chapter 2 Global Meningococcal Disease Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Meningococcal Disease Treatment (Volume and Value) by Type
2.3 Global Meningococcal Disease Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Meningococcal Disease Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Meningococcal Disease Treatment Market Analysis
Chapter 6 East Asia Meningococcal Disease Treatment Market Analysis
Chapter 7 Europe Meningococcal Disease Treatment Market Analysis
Chapter 8 South Asia Meningococcal Disease Treatment Market Analysis
Chapter 9 Southeast Asia Meningococcal Disease Treatment Market Analysis
Chapter 10 Middle East Meningococcal Disease Treatment Market Analysis
Chapter 11 Africa Meningococcal Disease Treatment Market Analysis
Chapter 12 Oceania Meningococcal Disease Treatment Market Analysis
Chapter 13 South America Meningococcal Disease Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Meningococcal Disease Treatment Business
Chapter 15 Global Meningococcal Disease Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027